Modifiable risk factors associated with tuberculosis disease in children in Pune, India

Citation: Jubulis J, Kinikar A, Ithape M, Khandave M, Dixit S, Hotalkar S, Kulkarni V, Mave V, Gupte N, Kagal A, Jain S, Bharadwaj R, Gupta A. Modifiable risk factors associated with tuberculosis disease in children in Pune, India. Int J Tuberc Lung Dis. 2014 Feb;18(2):198-204. doi: 10.5588/ijtld.13.0314. PMID: 24429313. PMCID: PMC4487622.

Access full article:

http://www.ncbi.nlm.nih.gov/pubmed/24429313

SETTING:

India accounts for the largest burden of tuberculosis (TB) worldwide, with 26% of the world's cases.

OBJECTIVE:

To assess the association between novel modifiable risk factors and TB in Indian children.

DESIGN:

Cases were children aged ≤ 5 years with confirmed/probable TB based on World Health Organization definitions (definition 1). Controls were healthy children aged ≤ 5 years. Logistic regression was performed to estimate the adjusted odds ratio (aOR) of being a TB case given exposure, including indoor air pollution (IAP; exposure to tobacco smoke and/or biomass fuels) and vitamin D deficiency. Cases were re-analyzed according to a new consensus research definition of pediatric TB (definition 2).

RESULTS:

Sixty cases and 118 controls were enrolled. Both groups had high levels of vitamin D deficiency (55% vs. 50%, P = 0.53). In multivariable analysis, TB was associated with household TB exposure (aOR 25.41, 95%CI 7.03-91.81), household food insecurity (aOR 11.55, 95%CI 3.33-40.15) and IAP exposure (aOR 2.67, 95%CI 1.02-6.97), but not vitamin D deficiency (aOR 1.00, 95%CI 0.38-2.66). Use of definition 2 reduced the number of cases to 25. In multivariate analysis, TB exposure, household food insecurity and IAP remained associated with TB.

CONCLUSIONS:

Household TB exposure, exposure to IAP and household food insecurity were independently associated with pediatric TB.

 Int J Tuberc Lung Dis 2014, 18(2):198-204; doi: 10.5588/ijtld.13.0314

Categories

CRS
Topics

Clinical Trials

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More

A5302:  BioBank for Surrogate Marker Research for TB...

Primary Objective To obtain sputum, serum, urine, and peripheral blood mononuclear cells (PBMCs) for central TB biorepository...

Read More

A5349: Rifapentine-containing treatment shortening regimens...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

Read More

A5128: Consent for Use of Stored Patient Specimens for...

The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other...

Read More